Ovarian cancer
Drug research and approvals for ovarian cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 774 studies of ovarian cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 113 drug trials for it since 2013, FDA has 19 approved and 65 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 774
- Trials authorized in Canada: 113
- FDA orphan approvals: 19
- EU medicines: 2
- INTEREST OF CAPA-MEDIUM CULTURE MEDIUM DURING IN VITRO MATURATION FOR THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME IN…NCT07951554 · Not applicable · Hospital St. Joseph, Marseille, France · starts Apr 8, 2026
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
- Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOSNCT07923552 · Not applicable · University Hospital, Clermont-Ferrand · starts Mar 14, 2025
- A Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid TumorsNCT07923214 · Phase 1 · Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · starts Jul 2, 2024
- The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world…NCT07916909 · Not reported · Women's Hospital School Of Medicine Zhejiang University · starts Jul 1, 2026
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- Phase 1 Study of VT-101 in Advanced Ovarian CancerNCT07905677 · Phase 1 · Michael J. Goodheart · starts Oct 26, 2026
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersNCT07902375 · Not applicable · Universiteit Antwerpen · starts Jun 19, 2026
Approved 13
- PaclitaxelTubulin inhibitor
- CarboplatinDNA inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- OlaparibPARP 1, 2 and 3 inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- TopotecanDNA topoisomerase I inhibitor
- NiraparibPoly [ADP-ribose] polymerase 2 inhibitor
- RucaparibPARP 1, 2 and 3 inhibitor
- AmifostineReactive metabolite scavenging agent
- TrabectedinDNA inhibitor
- Mirvetuximab soravtansineOvarian epithelial cancer · Folate receptor alpha binding agent
- IgovomabMucin-16 binding agent
Phase 3 12 of 51
- CisplatinDNA inhibitor
- CyclophosphamideDNA inhibitor
- DocetaxelTubulin inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- RivoceranibVascular endothelial growth factor receptor 2 inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- Fluzoparib
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- AvelumabProgrammed cell death 1 ligand 1 other
- CediranibStem cell growth factor receptor inhibitor
- OregovomabMucin-16 other
- VeliparibPARP 1, 2 and 3 inhibitor
Phase 2 12 of 207
- PembrolizumabProgrammed cell death protein 1 inhibitor
- AldesleukinInterleukin-2 receptor agonist
- Fludarabine
- OxaliplatinDNA inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- CapecitabineThymidylate synthase inhibitor
- GefitinibEpidermal growth factor receptor erbB1 inhibitor
- ImatinibTyrosine-protein kinase ABL inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- CatumaxomabT cell surface glycoprotein CD3 cross-linking agent
- TemsirolimusFK506-binding protein 1A inhibitor
Phase 1 or earlier 12 of 96
- ThiotepaDNA inhibitor
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Maveropepimut-s
- SonidegibSmoothened homolog inhibitor
- Interferon alfa-2bInterferon alpha/beta receptor agonist
- RintatolimodToll-like receptor 3 agonist
- SS1(DSFV)-PE38Mesothelin binding agent
- Contusugene ladenovecCellular tumor antigen p53 exogenous gene
- ValspodarP-glycoprotein 1 inhibitor
- Hiltonol
- QS-21
- AlemtuzumabCAMPATH-1 antigen inhibitor
How its trials ended
2,215 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 523 whose ending is known, 28% met their primary endpoint, 10% missed it and 62% stopped early.
- Completed, result not reported73633%
- Ongoing65129%
- Status unknown30514%
- Met its primary endpoint1467%
- Stopped: other or unclear1447%
- Stopped: enrollment or feasibility703%
- Missed its primary endpoint542%
- Stopped: sponsor or business decision542%
- Stopped: lack of efficacy352%
- Stopped: funding141%
- Stopped: safety6<1%
| Sep 23, 2026 | A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab) | Merck & Co. (MSD) | Pending |
| Aug 26, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan with or without bevacizumab versus standard of care as second- or third-line maintenance…AZD5335 / Avastin / Vegzelma | AstraZeneca Pharmaceuticals | Pending |
| Aug 26, 2026 | A phase 3, randomized, open-label study of raludotatug deruxtecan (mk 5909, r-dxd) maintenance treatment with or without bevacizumab versus standard of care in…Raludotatug deruxtecan (r-dxd) (MK-5909)) | Merck & Co. (MSD) | Pending |
| Aug 20, 2026 | A randomised, open-label, phase III study of torvutatug samrotecan in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance…Torvutatug samrotecan (AZD5335) / Avastin (bevacizumab) / Vegzelma (bevacizumab) | AstraZeneca Pharmaceuticals | Pending |
| Aug 11, 2026 | A randomized, open-label, phase 3 study of rina-s ± bevacizumab versus investigator's choice of platinum-based chemotherapy ± bevacizumab as 2l treatment in…GEN1184 / Vegzelma / Paclitaxel ribosepharm / Carboplatin hikma / Caelyx… | Genmab | Pending |
| Jul 29, 2026 | A randomized, open-label, multicenter, phase 3 study to investigate mocertatug rezetecan with or without bevacizumab in comparison to active observation with…Mocertatug rezetecan (GSK5733584) / Avastin / Zirabev | GSK | Ongoing |
| Jul 3, 2026 | A randomized, open-label, multicenter, phase 3 study to investigate mocertatug rezetecan with bevacizumab compared with platinum doublet with bevacizumab in…Mocertatug rezetecan (GSK5733584), paclitaxel, carboplatin,… | GSK | Ongoing |
| Jun 11, 2026 | A phase 3, randomized, open-label study of INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with…INCB123667 | Incyte | Ongoing |
| May 29, 2026 | A randomized, open-label, phase 3 study of rinatabart sesutecan (rina-s) plus standard of care versus standard of care as maintenance treatment after 2l…Rinatabart sesutecan (rina-s, PRO1184, GEN1184) / Vegzelma | Genmab | Pending |
| May 22, 2026 | A multicenter, first-in-human, dose escalation and optimization phase I/IIa study to investigate safety, tolerability, pharmacokinetics, and efficacy of the…TUB-040 | Tubulis GmbH | Pending |
| May 8, 2025 | Avmapki Fakzynja Co-PackTreatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy | Verastem, Inc. | Approved |
| Nov 14, 2022 | ElahereTreatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary… | ImmunoGen, Inc. | Approved |
| Nov 29, 2021 | CytaluxAs an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer | On Target Laboratories, Inc. | Approved |
| May 8, 2020 | LynparzaLynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian,… | AstraZeneca Pharmaceuticals LP | Approved |
| Apr 29, 2020 | ZejulaZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal… | GlaxoSmithKline, LLC. | Approved |
| Oct 23, 2019 | ZejulaZEJULA? is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been… | GlaxoSmithKline, LLC. | Approved |
| Dec 19, 2018 | LynparzaLynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic… | AstraZeneca Pharmaceuticals LP | Approved |
| Jun 13, 2018 | AvastinAvastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients… | Genentech, Inc. | Approved |
| Apr 6, 2018 | RubracaFor the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in… | pharma& | Approved |
| Aug 17, 2017 | LynparzaMaintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a… | AstraZeneca Pharmaceuticals LP | Approved |
| Mar 27, 2017 | ZejulaIndicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who… | GlaxoSmithKline, LLC. | Approved |
| Dec 19, 2016 | RubracaAs monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer… | pharma& | Approved |
| Dec 6, 2016 | AvastinAvastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with… | Genentech, Inc. | Approved |
| Dec 19, 2014 | LynparzaIndicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test)… | AstraZeneca Pharmaceuticals LP | Approved |
| Nov 14, 2014 | AvastinIn combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent… | Genentech, Inc. | Approved |
| Dec 16, 2014 | LynparzaOlaparib | AstraZeneca AB | EMA ↗ |
| Jun 20, 1996 | Caelyx pegylated liposomalDoxorubicin | Baxter Holding B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA